Nyxoah Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Olivier Taelman

Amministratore delegato

€807.1k

Compenso totale

Percentuale dello stipendio del CEO	54.1%
Mandato del CEO	5yrs
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	4.5yrs

Aggiornamenti recenti sulla gestione

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

Jun 05

Recent updates

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

Jun 05

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

Jan 24

Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?

Dec 21

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Olivier Taelman rispetto agli utili di Nyxoah?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-€53m
Jun 30 2024	n/a	n/a	-€44m
Mar 31 2024	n/a	n/a	-€43m
Dec 31 2023	€807k	€436k	-€43m
Sep 30 2023	n/a	n/a	-€46m
Jun 30 2023	n/a	n/a	-€44m
Mar 31 2023	n/a	n/a	-€36m
Dec 31 2022	€631k	€436k	-€31m
Sep 30 2022	n/a	n/a	-€24m
Jun 30 2022	n/a	n/a	-€27m
Mar 31 2022	n/a	n/a	-€29m
Dec 31 2021	€731k	€413k	-€28m
Sep 30 2021	n/a	n/a	-€25m
Jun 30 2021	n/a	n/a	-€21m
Mar 31 2021	n/a	n/a	-€16m
Dec 31 2020	€336k	€263k	-€12m

Compensazione vs Mercato: La retribuzione totale di Olivier ($USD 840.46K ) è circa la media per le aziende di dimensioni simili nel mercato Belgian ($USD 777.51K ).

Compensazione vs guadagni: La retribuzione di Olivier è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Olivier Taelman (53 yo)

5yrs

Mandato

€807,096

Compensazione

Mr. Olivier Taelman serves as a Vice President of Sales Europe at Autonomic Technologies, Inc. Mr. Olivier Taelman is the Chief Executive Officer at Nyxoah S.A. since November 2019 and serves as its Execu...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Taub	Co-Founder & Chairman	15.3yrs	€127.63k	7.55% € 22.7m
Olivier Taelman	CEO & Executive Director	5yrs	€807.10k	Nessun dato
Loic Moreau	President of International	no data	€468.69k	0.035% € 106.4k
John Landry	Chief Financial Officer	no data	Nessun dato	Nessun dato
Bruno Onkelinx	Chief Technology Officer	3.7yrs	Nessun dato	Nessun dato
Mikaela Kirkwood	Corporate Communication & Investor Relations Manager	no data	Nessun dato	Nessun dato
An Moonen	General Counsel	3.9yrs	Nessun dato	Nessun dato
Maggie McGowan	Chief HR Officer	less than a year	Nessun dato	Nessun dato
Remi Renard	Chief of Staff	less than a year	Nessun dato	Nessun dato
Jeyakumar Subbaroyan	Chief Clinical Officer	1.1yrs	Nessun dato	Nessun dato
Francis Kim	Chief Regulatory & Quality Officer	less than a year	Nessun dato	Nessun dato
Maurits Boon	Chief Medical Officer	less than a year	Nessun dato	Nessun dato

0.9yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di NYXH non è considerato esperto (durata media 0.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Taub	Co-Founder & Chairman	15.3yrs	€127.63k	7.55% € 22.7m
Olivier Taelman	CEO & Executive Director	4.2yrs	€807.10k	Nessun dato
Kevin Rakin	Independent Non-Executive Director	8.4yrs	€68.59k	0.33% € 992.9k
Jurgen Hambrecht	Independent Non-Executive Director	4.8yrs	€58.50k	3.59% € 10.8m
Daniel Wildman	Independent Non-Executive Director	1.8yrs	€71.28k	Nessun dato
Virginia Kirby	Independent Non-Executive Director	2.4yrs	€59.22k	0.015% € 44.7k
Rita Johnson-Mills	Independent Non-Executive Director	3.3yrs	€63.62k	0.015% € 44.7k
Pierre Gianello	Non-Executive Director	6.8yrs	€175.63k	0.031% € 92.9k

4.5yrs

Durata media

67yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NYXH sono considerati esperti (durata media dell'incarico 4.5 anni).

Nyxoah Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Nyxoah S.A. Appoints Scott Holstine as Chief Commercial Officer

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

Nyxoah S.A., Annual General Meeting, Jun 12, 2024

Nyxoah S.A. Appoints Christoph Eigenmann as Chief Commercial Officer

Nyxoah S.A. Appoints Daniel Wildman as Independent Director to Its Board of Directors

Nyxoah S.A. Announces Resignation of Raymond Cohen as Member of the Board of Directors

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: €0.50 loss per share (vs €0.27 loss in 3Q 2023)

Nyxoah S.A. to Report Fiscal Year 2024 Results on Mar 13, 2025

Nyxoah S.A. Presents Dream U.S. Study Data At Isss 2024, Showing Significant Ahi Reduction and Quality-Of-Life Improvements

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nyxoah S.A. Appoints Scott Holstine as Chief Commercial Officer

Price target decreased by 7.6% to €13.40

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA

It's Probably Less Likely That Nyxoah S.A.'s (EBR:NYXH) CEO Will See A Huge Pay Rise This Year

New minor risk - Shareholder dilution

Nyxoah S.A. has filed a Follow-on Equity Offering.

First quarter 2024 earnings released: €0.41 loss per share (vs €0.46 loss in 1Q 2023)

Full year 2023 earnings released: €1.51 loss per share (vs €1.21 loss in FY 2022)

New major risk - Revenue and earnings growth

Nyxoah S.A., Annual General Meeting, Jun 12, 2024

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

New major risk - Share price stability

Price target decreased by 13% to €9.65

Nyxoah SA Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio(R)

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Revenue and earnings growth

New major risk - Financial position

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 14%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings released: €0.45 loss per share (vs €0.19 loss in 2Q 2022)

First quarter 2023 earnings released: €0.46 loss per share (vs €0.26 loss in 1Q 2022)

Nyxoah S.A. Appoints Christoph Eigenmann as Chief Commercial Officer

Full year 2022 earnings released: €1.21 loss per share (vs €1.16 loss in FY 2021)

Nyxoah S.A. to Report Q3, 2023 Results on Nov 08, 2023

Nyxoah S.A. Appoints Daniel Wildman as Independent Director to Its Board of Directors

Third quarter 2022 earnings released: €0.24 loss per share (vs €0.29 loss in 3Q 2021)

Nyxoah S.A. Announces Resignation of Raymond Cohen as Member of the Board of Directors

Second quarter 2022 earnings released: €0.19 loss per share (vs €0.31 loss in 2Q 2021)

Nyxoah S.A. Announces CE Mark Approval for Genio® 2.1

Nyxoah SA Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio in Complete Concentric Collapse Patients

Nyxoah S.A. Announces U.S. Food and Drug Administration Approved the Use of Nyxoah's Next Generation Genio 2.1 System

Nyxoah S.A. Announces Board Changes

Nyxoah S.A. to Report First Half, 2022 Results on Aug 09, 2022

Nyxoah S.A. to Report Fiscal Year 2021 Results on Mar 24, 2022

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Nyxoah Deleted from Other OTC

Nyxoah SA's BETTER SLEEP Trial Reaches its Primary Endpoints

New 90-day high: €19.90

Nyxoah Receives FDA Approval for Full-Body 1.5T and 3T MRI Compatibility for the Genio System to Treat Obstructive Sleep Apnea

New 90-day high: €18.50

Nyxoah S.A. Announces First US Patient Implanted in the DREAM Pivotal IDE Study, with the Genio System for the Treatment of Obstructive Sleep Apnea

Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?

Nyxoah S.A. Announces First Patient Implanted in the Dream US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea

Nyxoah S.A. has filed an IPO in the amount of €75.67805 million.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media